After a financial maneuver by Legend Biotech, GenScript Biotech no longer considers itself the cell therapy biotech’s majority shareholder. (pengtianli/iStock/Getty ...
Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its 48% holding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
